CL2020002544A1 - Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret - Google Patents

Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret

Info

Publication number
CL2020002544A1
CL2020002544A1 CL2020002544A CL2020002544A CL2020002544A1 CL 2020002544 A1 CL2020002544 A1 CL 2020002544A1 CL 2020002544 A CL2020002544 A CL 2020002544A CL 2020002544 A CL2020002544 A CL 2020002544A CL 2020002544 A1 CL2020002544 A1 CL 2020002544A1
Authority
CL
Chile
Prior art keywords
ret
treating cancer
alteration
inhibitor
ret inhibitor
Prior art date
Application number
CL2020002544A
Other languages
English (en)
Inventor
Raab Erica Evans
Beni B Wolf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66223846&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020002544(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of CL2020002544A1 publication Critical patent/CL2020002544A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se describe en la presente el tratamiento de un sujeto afectado por un cáncer que tiene una alteración de RET activadora al administrar una cantidad efectiva de un inhibidor de RET selectivo, por ejemplo, Compuesto 1 o sales farmacéuticamente aceptables del mismo, incluyendo, por ejemplo, administrar una cantidad de 300 mg a 400 mg del inhibidor de RET selectivo una vez al día.
CL2020002544A 2018-04-03 2020-10-01 Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret CL2020002544A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862652284P 2018-04-03 2018-04-03
US201862656297P 2018-04-11 2018-04-11
US201862657605P 2018-04-13 2018-04-13
US201862741683P 2018-10-05 2018-10-05

Publications (1)

Publication Number Publication Date
CL2020002544A1 true CL2020002544A1 (es) 2021-06-11

Family

ID=66223846

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002544A CL2020002544A1 (es) 2018-04-03 2020-10-01 Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret

Country Status (26)

Country Link
US (5) US20210100795A1 (es)
EP (2) EP4353317A3 (es)
JP (3) JP7422084B2 (es)
KR (1) KR20200139749A (es)
AU (1) AU2019247766A1 (es)
BR (1) BR112020020273A2 (es)
CA (1) CA3096043A1 (es)
CL (1) CL2020002544A1 (es)
CR (1) CR20200522A (es)
DK (1) DK3773589T3 (es)
ES (1) ES2970041T3 (es)
FI (1) FI3773589T3 (es)
HR (1) HRP20240124T1 (es)
HU (1) HUE065374T2 (es)
IL (1) IL277629A (es)
LT (1) LT3773589T (es)
MX (1) MX2020010417A (es)
MY (1) MY203645A (es)
PE (1) PE20210096A1 (es)
PL (1) PL3773589T3 (es)
PT (1) PT3773589T (es)
RS (1) RS65127B1 (es)
SG (1) SG11202009681YA (es)
SI (1) SI3773589T1 (es)
WO (1) WO2019195471A1 (es)
ZA (1) ZA202006072B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
SG11202009681YA (en) 2018-04-03 2020-10-29 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
US11666570B2 (en) * 2019-07-11 2023-06-06 The Board Of Trustees Of The Leland Stanford Junior University Diagnosis and regulation of epidermal differentiation and cancer cell activity
WO2021243192A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CR20220666A (es) 2020-05-29 2023-05-05 Blueprint Medicines Corp Composiciones farmacéuticas de pralsetinib
US11946935B2 (en) * 2020-08-25 2024-04-02 Regents Of The University Of Minnesota Circulating tumor markers for meningiomas
JP1746261S (ja) * 2022-10-17 2023-06-14 量子暗号鍵伝送機

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030024659A (ko) 2000-02-17 2003-03-26 암겐 인코포레이티드 키나제 억제제
WO2004009087A1 (en) 2002-07-24 2004-01-29 University Of Cincinnati 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases
JP5138938B2 (ja) 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Ｒｅｔ調節剤の開発のための化合物および方法
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
AU2006244203B2 (en) 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
WO2006128042A2 (en) 2005-05-26 2006-11-30 The Johns Hopkins University Methods of identifying mutations in nucleic acid
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
WO2007087245A2 (en) 2006-01-24 2007-08-02 Merck & Co., Inc. Ret tyrosine kinase inhibition
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
US20090048214A1 (en) 2006-11-15 2009-02-19 Rigel Pharmaceuticals, Inc Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds
WO2009003136A1 (en) 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
JP2010533158A (ja) 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物類−９４５
BRPI0814441A2 (pt) 2007-07-19 2015-07-14 Schering Corp Compostos de amida heterocíclica como inibidores de proteína cinase
WO2009018415A1 (en) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
WO2009100536A1 (en) 2008-02-15 2009-08-20 Methylgene Inc. Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures
EP2313091A4 (en) 2008-07-14 2012-04-04 Univ Kingston PHARMACEUTICAL COMPOSITIONS WITH RET-HEMMERN AND METHOD FOR THE TREATMENT OF CANCER
AU2010229140A1 (en) 2009-03-24 2011-11-10 Msd K.K. Novel aminopyridine derivatives having Aurora A selective inhibitory action
EP2440052A4 (en) 2009-06-08 2013-01-23 Abraxis Bioscience Llc TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
EP2440053A4 (en) 2009-06-09 2012-10-31 California Capital Equity Llc BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
PH12012500809A1 (en) 2009-10-30 2012-11-26 Ariad Pharma Inc Methods and compositions for treating cancer
CA2780892C (en) 2009-11-13 2017-02-14 Genosco Kinase inhibitors
WO2013018882A1 (ja) 2011-08-04 2013-02-07 独立行政法人国立がん研究センター Ｋｉｆ５ｂ遺伝子とｒｅｔ遺伝子との融合遺伝子、並びに該融合遺伝子を標的としたがん治療の有効性を判定する方法
WO2013028817A1 (en) 2011-08-23 2013-02-28 Foundation Medicine , Inc. Novel kif5b-ret fusion molecules and uses thereof
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US20130096136A1 (en) 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
US10023855B2 (en) 2011-10-31 2018-07-17 Macrogen, Inc. Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
JP2015109806A (ja) 2012-03-22 2015-06-18 アステラス製薬株式会社 新規ｒｅｔ融合体の検出法
ES2645984T3 (es) 2012-04-25 2017-12-11 Raqualia Pharma Inc Derivados de pirrolopiridinona como bloqueadores de TTX-S
US20150099721A1 (en) 2012-05-10 2015-04-09 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
NZ703495A (en) 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
JPWO2014017491A1 (ja) 2012-07-26 2016-07-11 国立研究開発法人国立がん研究センター Ｃｅｐ５５遺伝子とｒｅｔ遺伝子との融合遺伝子
JP6513567B2 (ja) 2012-09-07 2019-05-15 エクセリクシス， インク． 肺腺癌の治療で使用するためのｍｅｔ、ｖｅｇｆｒ、およびｒｅｔの阻害剤
PL2902029T3 (pl) 2012-09-25 2019-01-31 Chugai Seiyaku Kabushiki Kaisha Inhibitor RET
EP2917214B1 (en) 2012-11-07 2019-08-28 Nerviano Medical Sciences S.r.l. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
BR112015019590A2 (pt) 2013-02-25 2017-07-18 Bristol Myers Squibb Co derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
MX2015012286A (es) 2013-03-15 2016-05-31 Glaxosmithkline Ip Dev Ltd Derivados de piridina como inhibidores de cinasa reordenada durante transfección.
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
WO2014147640A2 (en) 2013-03-19 2014-09-25 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for the preparation of anagliptin
WO2015006875A1 (en) 2013-07-18 2015-01-22 Methylgene Inc. Process for the preparation of substituted pyrimidines
EP3037547A1 (en) 2013-08-20 2016-06-29 National Cancer Center New fusion gene detected in lung cancer
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
MX365614B (es) 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.
PT3395814T (pt) 2013-10-25 2022-07-27 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
EP3517526B1 (en) 2014-09-10 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Pyridinones as rearranged during transfection (ret) inhibitors
BR112017004897A2 (pt) 2014-09-10 2017-12-12 Glaxosmithkline Ip Dev Ltd compostos inovadores como inibidores rearranjados durante a transfecção (ret)
EP3218378B1 (en) 2014-11-14 2020-01-08 Nerviano Medical Sciences S.r.l. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
CN104844567B (zh) 2015-04-23 2017-03-29 暨南大学 一种中间体1‑(3‑氯‑2‑吡啶基)‑3‑溴‑1h‑5‑吡唑甲酸的合成方法
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
BR112018001190A2 (pt) 2015-07-24 2018-09-11 Blueprint Medicines Corp composições úteis para tratar distúrbios relacionados a kit e pdfgr
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
CN105255927B (zh) 2015-09-30 2018-07-27 温州医科大学附属第一医院 一种kiaa1217-ret融合基因
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
BR112018008908A2 (pt) 2015-11-02 2018-11-27 Janssen Pharmaceutica Nv anticorpos anti-il1rap, moléculas de ligação ao antígeno biespecíficas que se ligam il1rap e cd3, e seus usos
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
WO2017145050A1 (en) 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
AR107912A1 (es) 2016-03-17 2018-06-28 Blueprint Medicines Corp Inhibidores de ret
US10576085B2 (en) 2016-04-01 2020-03-03 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
HRP20221051T8 (hr) 2016-04-15 2023-07-21 Cancer Research Technology Limited Heterociklički spojevi kao inhibitori ret kinaze
KR102706837B1 (ko) 2016-04-15 2024-09-19 캔써 리서치 테크놀로지 리미티드 Ret 키나아제 억제제로서의 헤테로사이클릭 화합물
FI3442977T3 (fi) 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
CN110022900A (zh) 2016-09-08 2019-07-16 蓝图药品公司 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合
JP2018052878A (ja) 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
CN106749231B (zh) 2016-10-09 2019-03-01 南京纳丁菲医药科技有限公司 萘啶化合物和药物组合物及它们的应用
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018102455A1 (en) 2016-12-01 2018-06-07 Ignyta, Inc. Methods for the treatment of cancer
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
US20210290620A1 (en) * 2017-05-15 2021-09-23 Blueprint Medicines Corporation Combinations of RET Inhibitors and mTORC1 Inhibitors and Uses Thereof for the Treatment of Cancer Mediated by Aberrant RET Activity
EP3641776B1 (en) 2017-06-23 2023-10-18 San Diego State University Research Foundation Atropisomerism for enhanced kinase inhibitor selectivity
CN109180677A (zh) 2017-06-30 2019-01-11 厦门大学 取代芳基醚类化合物、其制备方法、药用组合物及其应用
ES3074838T3 (es) 2017-07-07 2026-07-23 Medicover Public Co Ltd Análisis paralelo multiplexado con enriquecimiento de blancos para la evaluación de biomarcadores tumorales
CN107980784B (zh) 2017-12-13 2020-05-26 中国农业大学 5-氨基吡唑类化合物在调节植物生长方面的应用
RS63787B1 (sr) 2017-12-19 2022-12-30 Turning Point Therapeutics Inc Makrociklična jedinjenja za lečenje bolesti
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN108341782A (zh) 2018-03-30 2018-07-31 南京哈柏医药科技有限公司 3-氨基-5-甲基吡唑的合成工艺
SG11202009681YA (en) 2018-04-03 2020-10-29 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
EP3833372A4 (en) 2018-08-10 2022-06-08 Blueprint Medicines Corporation TREATMENT OF EGFR MUTANT CANCER
CN111440151A (zh) 2020-03-25 2020-07-24 魏威 制备抗肿瘤药普拉赛替尼的方法
CN111362923A (zh) 2020-03-25 2020-07-03 魏威 制备ret抑制剂普拉塞替尼的方法、以及普拉塞替尼的中间体及其制备方法
WO2021243192A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CR20220666A (es) 2020-05-29 2023-05-05 Blueprint Medicines Corp Composiciones farmacéuticas de pralsetinib
US20240059672A1 (en) 2020-12-04 2024-02-22 Blueprint Medicines Corporation Method of preparing pralsetinib

Also Published As

Publication number Publication date
US20250041297A1 (en) 2025-02-06
JP2022022391A (ja) 2022-02-03
EP4353317A2 (en) 2024-04-17
CA3096043A1 (en) 2019-10-10
US20210100799A1 (en) 2021-04-08
US20220175773A1 (en) 2022-06-09
JP2021520349A (ja) 2021-08-19
CR20200522A (es) 2021-02-17
US20210085680A1 (en) 2021-03-25
JP7422084B2 (ja) 2024-01-25
MX2020010417A (es) 2021-01-08
US11872192B2 (en) 2024-01-16
US11963958B2 (en) 2024-04-23
IL277629A (en) 2020-11-30
PT3773589T (pt) 2024-02-06
SG11202009681YA (en) 2020-10-29
FI3773589T3 (fi) 2024-02-01
ZA202006072B (en) 2024-01-31
HUE065374T2 (hu) 2024-05-28
PL3773589T3 (pl) 2024-04-02
BR112020020273A2 (pt) 2021-04-06
US11273160B2 (en) 2022-03-15
PE20210096A1 (es) 2021-01-12
WO2019195471A1 (en) 2019-10-10
ES2970041T3 (es) 2024-05-24
EP3773589A1 (en) 2021-02-17
EP4353317A3 (en) 2024-05-08
AU2019247766A1 (en) 2020-10-15
DK3773589T3 (da) 2024-01-29
LT3773589T (lt) 2024-02-12
MY203645A (en) 2024-07-11
RS65127B1 (sr) 2024-02-29
EP3773589B1 (en) 2023-11-01
SI3773589T1 (sl) 2024-03-29
US20210100795A1 (en) 2021-04-08
KR20200139749A (ko) 2020-12-14
HRP20240124T1 (hr) 2024-04-12
US12539303B2 (en) 2026-02-03
JP2023165937A (ja) 2023-11-17
RU2020135917A (ru) 2022-05-04

Similar Documents

Publication Publication Date Title
CR20200522A (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
BR112022001393A2 (pt) Forma cristalina do inibidor de atr e seu uso
CL2023000289A1 (es) Combinaciones para el tratamiento de cáncer
CR20210368A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
CL2021002966A1 (es) Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer.
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
MX2021002322A (es) Nuevos metodos.
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2019002265A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
AR101740A1 (es) Terapia de combinación y composiciones
CL2015001923A1 (es) Uso de crenolanib para el tratamiento de trastornos proliferativos que tiene flt3 mutado
CL2019003402A1 (es) Composiciones sólidas para administración oral.
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
MX2019002121A (es) Tratamiento conjunto para tratar el cancer de pancreas.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca